HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Coagulation-monitored, dose-adjusted catheter-directed thrombolysis or pharmaco-mechanical thrombus removal in deep vein thrombosis.

Abstract
Background: Pharmaco-mechanical thrombectomy (PMT) and catheter-directed thrombolysis (CDT) are therapeutic options for selected patients with acute deep vein thrombosis (DVT) to prevent post-thrombotic syndrome (PTS). Patients and methods: We aimed to describe the clinical characteristics and outcomes of 159 patients with symptomatic iliofemoral DVT undergoing PMT alone, CDT alone, or CDT followed by PMT (bail-out) in the Swiss Venous Stent Registry. The primary outcome was the incidence of peri-interventional major and minor bleeding complications (ISTH criteria). Secondary outcomes included the incidence of PTS and stent patency after 3 years. Results: Mean age was 49±20 years and 58% were women. DVT involved the iliac veins in 99% of patients, whereas 53% had an underlying iliac vein compression. PMT alone was used in 40 patients, CDT alone in 77, and 42 received initial CDT followed by bail-out PMT due to insufficient thrombus clearance. Single-session PMT was the preferred approach in patients with iliac vein compression, patent popliteal vein, and absence of IVC thrombus. Patients treated with PMT alone received a lower r-tPA dose (median 10 mg, IQR 10-10) vs. those treated with CDT (20 mg, IQR 10-30). The rate of peri-interventional major bleeding was 0%, 1%, and 2%, whereas that of minor bleeding was 0%, 1%, and 12%, respectively, all occurring during CDT. After 3 years, PTS occurred in 6%, 9%, and 7% of patients, respectively. The primary stent patency rate was 95%, 88%, and 83%, respectively. Conclusions: The use of PMT and CDT for iliofemoral DVT was overall safe and resulted in high long-term patency and treatment success. Given the less severe presentation of DVT, single-session PMT appeared to be characterized by numerically better primary patency and lower perioperative bleeding event rates than CDT.
AuthorsJulian Kleine Wortmann, Stefano Barco, Riccardo M Fumagalli, Davide Voci, Ulrike Hügel, Rahel Cola, David Spirk, Nils Kucher, Tim Sebastian
JournalVASA. Zeitschrift fur Gefasskrankheiten (Vasa) Vol. 52 Issue 6 Pg. 416-422 (Nov 2023) ISSN: 0301-1526 [Print] Switzerland
PMID37847240 (Publication Type: Journal Article)
Chemical References
  • Fibrinolytic Agents
Topics
  • Humans
  • Female
  • Adult
  • Middle Aged
  • Aged
  • Male
  • Thrombolytic Therapy (adverse effects)
  • Thrombectomy (adverse effects, methods)
  • Venous Thrombosis (diagnostic imaging, therapy, complications)
  • Postthrombotic Syndrome (etiology, prevention & control)
  • Catheters (adverse effects)
  • Hemorrhage (chemically induced)
  • Treatment Outcome
  • Iliac Vein (diagnostic imaging, surgery)
  • Retrospective Studies
  • Fibrinolytic Agents (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: